Entelos Inc.



ENTELOS, Inc.

("Entelos" or "the Company")

Trading Statement

Entelos, Inc. (LSE:ENTL), today is updating the market ahead of its pre-close
period for the six-month period ended 30 June 2008.

Trading has been in line with management expectations. The Company has good
contract visibility and has approximately 70% of its 2008 annual revenue
expectation under contract as at 30 June 2008. Cash, investments, and accounts
receivable totaled $8.5 million as at 30 June 2008 versus $5.7 million at the
end of the same period one year ago.

Since its preliminary results report on 16 April, Entelos entered a new
multi-million dollar research contract focused on cardiovascular risk reduction,
joined a three-year consortium funded by Pfizer to find new targets in diabetes
and obesity, and entered into an agreement with Eli Lilly to conduct in silico
research in diabetes with the Entelos Metabolism PhysioLab(R). Lilly also
exercised its option to purchase a perpetual license to Entelos' proprietary
DrugMatrix(R) database, the world's largest reference database linking gene
expression profiles of over 630 drugs to results from traditional preclinical
pharmacology, safety, and toxicity tests. Separately, the Company was recently
granted a new U.S. patent for a liver toxicity screening test derived from
DrugMatrix.

Entelos' in silico R&D and toxicology services, which include clinical trial
simulations and predictive "virtual patient populations", help to lower the
risk, time, and cost of drug R&D by strategically selecting optimal doses,
patient types, clinical trial designs and drug combinations that are both
effective and safe.

In addition, the Company continues to strengthen its global business development
capability and to broaden its technology applications to other health-related
markets such as consumer products and personalized medicine.

Enquiries

Entelos, Inc.
Alan Blazei, Chief Financial Officer                Tel: +1 650 572 5400
Jill Fujisaki, Vice President, Investor Relations

KBC Peel Hunt, Ltd (Nominated Advisor and Broker)
Capel Irwin/David Anderson                          Tel: +44 (0) 20 4718 8900

Buchanan Communications
Lisa Baderoon/Mary-Jane Johnson                     Tel: +44 (0)20 7466 5000

About Entelos, Inc.

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines are
discovered, developed, and utilized. The Company leverages its proprietary in
silico disease models, "virtual human" technology, and toxicology reference
systems to develop safer and more effective drugs, improve the quality of
health-related consumer products, and deliver on the promise of personalized
medicine. Entelos provides customized products, technology and research services
to global pharmaceutical, health-care, and consumer products companies in safety
testing, arthritis, cardiovascular diseases, asthma, obesity, diabetes,
hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal
care products.
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Entelos Regs Charts.
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Entelos Regs Charts.